



2024 HOT TOPIC IN BASIC & TRANSLATIONAL SCIENCE: **TOLERANCE & RESISTANCE TO TARGETED THERAPY IN NSCLC**

DECEMBER 13-15, 2024



WASHINGTON, DC

Abstract Timeline

| | |
|-----------|-----------------------------------|
| May 29 | Launch Abstract Submission System |
| July 10 | Abstract Submission Deadline |
| July 29 | Abstract Notifications |
| August 30 | Early Registration Deadline |

Abstract Submission Guidelines

| | |
|------------------------|--|
| Abstract Word Limit: | 400 words in length (does not include title and authors) |
| Title Character Limit: | 125 characters in length |
| Abstract Format: | Abstracts should be organized with headings: Background, Method, Results, Conclusions. Content of the abstract will be uploaded as plain text within the Abstract Submission Portal. |
| Tables: | No limit, each table counts as 100 words |
| Images: | 2 maximum, each image counts as 100 words |
| Format(s): | Upload tables, images and graphs in GIF, JPEG, JPG or PNG format of a minimum of 300 dpi and 100% size. |
| Language: | English |
| Fee: | No fee |
| Submission Limit: | No limit to the numbers of abstracts an author can submit |
| Number of co-authors: | No limit |

Encore Submission: An abstract that has previously been presented at another meeting will only be considered if there have been significant updates to the abstract. Submitters are required to list any previously presented abstracts in the introduction of the abstract.

Late-Breaking Abstract (LBA) Submission: LBA designation will only be given to impactful prospective studies that will change clinical practice within the year and whose data are not available at the time of regular abstract submission due to study events and/or timelines. Authors of LBA must submit a place holder abstract through the abstract portal by July 10, 2024

Required sections for LBA place holder, which must be submitted by the July 10, 2024 deadline:

- Explanation of why the abstract qualifies as late-breaking
- Introduction
- Methods, including applicable endpoints
- Types of anticipated analysis and data to be reported

Trial in Progress: HTTR 2024 does not accept the submissions of trials in progress.

Case Report: HTTR 2024 does not accept the submissions of case reports.

Publication: Authors must agree to allow publication of accepted abstract(s) in the Journal of Thoracic Oncology (JTO) and the conference website. Most abstracts will be published and released prior to the meeting, except for embargoed abstracts which will be posted on the day of presentation.

Topics/Tracks:

- Tumor Biology - Preclinical Biology
- Tumor Biology - Translational Biology
- Pathology and Biomarkers
- Early-Stage Non-small Cell Lung Cancer
- Local-Regional Non-small Cell Lung Cancer
- Metastatic Non-small Cell Lung Cancer